Pfizer was founded in New York City in 1849 by two German immigrants, Charles Pfizer and Charles Erhart. The company initially operated as a fine chemicals business (their first product was a palatable anti-parasitic drug that tasted like toffee). The defining, substantial transformation of Pfizer occurred during World War II when the company perfected the complex, considerable deep-tank fermentation process required to mass-produce penicillin, essentially becoming the primary supplier of antibiotics to the Allied forces. This established Pfizer's, multi-decade reputation as an undisputed powerhouse of large-scale chemical manufacturing.
The Era of the Megablockbuster (Lipitor and Viagra)
In the late 1990s and 2000s, Pfizer defined the modern "megablockbuster" era of the pharmaceutical industry. The strategy was reliant on considerable, direct-to-consumer television advertising (which had just been legalized in the US). Pfizer commercialized Viagra, creating a significant, multi-billion-dollar global market. However, the clear crown jewel of the empire was Lipitor (a statin drug that lowered cholesterol, acquired through the hostile takeover of Warner-Lambert in 2000). Lipitor became the highest-selling pharmaceutical product in human history, generating over $125 billion in lifetime sales and providing Pfizer with major, nearly infinite cash flow to acquire formidable competitors (like Wyeth in 2009).
The Patent Cliff and the Bourla Reorganization
In 2011, Pfizer faced the most brutal "patent cliff" in corporate history: the US patent for Lipitor expired, and the extensive revenue instantly evaporated due to cheap generic competition. For the next decade, Pfizer struggled to find a replacement for that lost revenue. In 2019, CEO Albert Bourla executed an aggressive, formidable corporate restructuring. He spun off Pfizer's vast consumer healthcare division (Advil, ChapStick) into a joint venture with GSK, and spun out the large, low-margin off-patent generic drug division (Upjohn) to merge with Mylan. Bourla intended to shrink Pfizer into a focused, pure-play, high-margin innovative biopharmaceutical company.
The COVID-19 Vaccine Windfall (Comirnaty)
Bourla's restructuring was immediately validated by the crisis of the COVID-19 pandemic. While competitors relied on government subsidies, Pfizer utilized its own balance sheet, partnering with a small German biotech firm (BioNTech) to quickly manufacture and distribute the revolutionary mRNA vaccine (Comirnaty) and the antiviral pill Paxlovid. The financial result was unprecedented in corporate history. In 2022, Pfizer generated a staggering $100 billion in revenue, printing, multi-billion-dollar profits by serving as the primary supplier of the vaccine to the United States and European governments.
The Post-Pandemic Hangover and M&A Strategy
Today Pfizer is suffering a prominent, painful post-pandemic hangover. As the global pandemic ended, the revenue from the COVID vaccine and Paxlovid violently collapsed, severely crushing the company's stock price and infuriating Wall Street. Pfizer faces a significant wave of upcoming patent expirations (specifically on its lucrative blood thinner, Eliquis). To survive Pfizer is deploying the prominent cash hoard it generated during the pandemic. In 2023, the company executed a vast, aggressive $43 billion acquisition of Seagen (a pioneer in targeted "antibody-drug conjugate" cancer therapies), desperately attempting to buy its way into the considerable, high-margin oncology market before its legacy patents expire.
